Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens

Journal of Rheumatology

Volumn 37, Issue 4, 2010, Pages 870-875

  Becker, Mara L ^a   Rosé, Carlos D ^b   Cron, Randy Q ^c   Sherry, David D ^d   Bilker, Warren B ^e   Lautenbach, Ebbing ^e  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c CHILDREN S HOSPITAL OF ALABAMA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Efficacy; Juvenile idiopathic arthritis; Methotrexate; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MEDICAL RECORDS; METHOTREXATE; PATIENT SELECTION; SEX FACTORS; TREATMENT OUTCOME;

EID: 77950646542     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090826     Document Type: Article

References (16)

1. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: A retrospective study. Arthritis Rheum 1986;29:801-807 (Pubitemid 16094160)
2. Speckmaier M, Findeisen J, Woo P, Hall A, Sills JA, Price T, et al. Low dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989;7:647-650 (Pubitemid 20100992)
3. Wallace CA, Sherry DD, Mellins ED, Aiken RP. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993;23:118-122 (Pubitemid 23049194)
4. Rose CD, Singsen BH, Eichenfield AH, Goldsmith DP, Athreya BH. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990;117:653-659 (Pubitemid 20332115)
5. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to subtype. Clin Exp Rheumatol 1991;9:297-302.
6. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-1049
7. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992;19:1604-1607
8. Reiff A, Shaham B, Wood, BP, Bernstein SP, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-118
9. Ruperto N, Murray K, Gerloni V, Wulffraat N, Knupp Feitosa de Olieira S, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-2201 (Pubitemid 38924397)
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-392 (Pubitemid 38160763)
11. Kremer JM, Alarcon GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-328
12. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209 (Pubitemid 27430130)
13. Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The long term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:2226-2234 (Pubitemid 28016420)
14. Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999;134:47-52.
15. Lahdenne P, Rapola J, Ylijoki H, Haapasaari J. Hepatotoxicity in patients with juvenile idiopathic arthritis receiving long term methotrexate therapy. J Rheumatol 2002;29:2442-2445 (Pubitemid 35266040)
16. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:2501-2506 (Pubitemid 39603104)